EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents

Jørn Herrstedt iD, L Celio, P J Hesketh, L Zhang, R Navari, A Chan, M Saito, R Chow, M Aapro

Supportive Care in Cancer · 2024-01 · 32 (1)

DOI: 10.1007/s00520-023-08221-4 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Supportive Care in Cancer, online erschienen am 21.12.2023. Verfasst von Jørn Herrstedt und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Zealand University Hospital, Sygehusvej 10, DK-4000, Roskilde, Denmark. jherr@regionsjaelland.dk. Hauptthemen laut MEDLINE: Antiemetics, Antineoplastic Agents. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, Copenhagen University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This systematic review updates the MASCC/ESMO recommendations for high-emetic-risk chemotherapy (HEC) published in 2016–2017. HEC still includes cisplatin, carmustine, dacarbazine, mechlorethamine, streptozocin, and cyclophosphamide in doses of > 1500 mg/m 2 and the combination of cyclophosphamide and an anthracycline (AC) in women with breast cancer.

Methods

A systematic review report following the PRISMA guidelines of the literature from January 1, 2015, until February 1, 2023, was performed. PubMed (Ovid), Scopus (Google), and the Cochrane Database of Systematic Reviews were searched. The literature search was limited to randomized controlled trials, systematic reviews, and meta-analyses.

Results

Forty-six new references were determined to be relevant. The main topics identified were (1) steroid-sparing regimens, (2) olanzapine-containing regimens, and (3) other issues such as comparisons of antiemetics of the same drug class, intravenous NK 1 receptor antagonists, and potentially new antiemetics. Five updated recommendations are presented.

Conclusion

There is no need to prescribe steroids (dexamethasone) beyond day 1 after AC HEC, whereas a 4-day regimen is recommended in non-AC HEC. Olanzapine is now recommended as a fixed part of a four-drug prophylactic antiemetic regimen in both non-AC and AC HEC. No major differences between 5-HT 3 receptor antagonists or between NK 1 receptor antagonists were identified. No new antiemetic agents qualified for inclusion in the updated recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntiemeticsAntineoplastic AgentsFemaleHumansEmeticsOlanzapineNauseaVomitingCyclophosphamideAnthracyclines

Stichwörter der Autor:innen

AntiemeticsGuidelineHECHigh-emetic-risk chemotherapyNauseaVomiting

Substanzen

EmeticsAntiemeticsOlanzapineAntineoplastic AgentsCyclophosphamideAnthracyclines

Autor:innen und Institutionen

  • Department of Clinical Oncology, Zealand University Hospital, Sygehusvej 10, DK-4000, Roskilde, Denmark. jherr@regionsjaelland.dk.
  • Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. jherr@regionsjaelland.dk.
  • , Milan, Italy.
  • Division of Hematology Oncology, Lahey Hospital and Medical Center, Burlington, MA, USA.
  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • World Health Organization, Birmingham, Alabama, USA.

ORCID-Profile: Jørn Herrstedt

Förderung

  • World Health Organization
  • Copenhagen University

Zitieren

APA

Herrstedt, J., Celio, L., Hesketh, P. J., Zhang, L., Navari, R., Chan, A., Saito, M., Chow, R., & Aapro, M. (2024). 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. Supportive Care in Cancer, 32(1). https://doi.org/10.1007/s00520-023-08221-4

Vancouver

Herrstedt J, Celio L, Hesketh PJ, Zhang L, Navari R, Chan A, et al. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. Supportive Care in Cancer. 2024;32(1). doi:10.1007/s00520-023-08221-4

BibTeX
@article{Herrstedt2024,
  author = {Herrstedt, Jørn and Celio, L and Hesketh, P J and Zhang, L and Navari, R and Chan, A and Saito, M and Chow, R and Aapro, M},
  title = {2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents},
  journal = {Supportive Care in Cancer},
  year = {2024},
  volume = {32},
  number = {1},
  doi = {10.1007/s00520-023-08221-4}
}
Kostenlos starten →